Clinical trials: Patients With Schizophrenia
Schizophrenia
Effects of Varenicline on Plasticity in Schizophrenia
This laboratory pilot study will explore the effects of varenicline tartrate on long-term potentiation (LTP)-like mechanisms of (1) the motor cortex and (2) the dorsolateral prefrontal cortex (DLPFC) and working memory in…
- Trial name
- VAR-PAS (NCT01934023)
- Testing
- Varenicline
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Agitation
Treating Acutely Agitated Patients With Asenapine Sublingual Tablets
Our proposal is to administer asenapine to patients who are clinically agitated and in need of immediate intervention. At present there are no controlled studies that we know of that explores the use of asenapine for this…
- Trial name
- NCT01400113
- Testing
- Asenapine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Unity Health Toronto
Substance Use Disorder, Attention Deficit Disorder With Hyperactivity
tRNS in Anterior Cingulate Cortex Reduces Craving Over Dual Pathology Patients
The purpose of this study is to study the efficacy and security of noninvasive brain stimulation as a new approach for patients with Substance Use Disorders (SUDs) plus other psychiatric conditions like ADHD, Schizophrenia…
- Conditions
- Substance Use Disorder, Attention Deficit Disorder With Hyperactivity, Bipolar Disorder, Schizophrenia
- Trial name
- tRND&SUDs (NCT01876524)
- Testing
- Transcranial Random Noise Stimulation
- Where
- Spain
- Volunteers
- 225 people
- Sponsor
- Spanish Foundation for Neurometrics Development
Autism Spectrum Disorders, Schizophrenia
Visual Exploration and Attention: Studies in Patients With Schizophrenia and Autism Spectrum Disorders
The aim of the protocol is to better understand the impairments in visual processing, as such impairments may induce social interaction difficulties in subjects with autism spectrum disorders (adults and children) and…
- Trial name
- NCT00914030
- Testing
- Neuropsychological evaluation
- Where
- 5 sites in France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Schizophrenia Disorders
The Effects of Mindfulness and Web-Based Physical Activity Program in Patients With Schizophrenia
This study was aimed to examine the effects of the Mindfulness and Web-Based Physical Activity Program - consisting of two weeks of mindfulness skills followed by 12 weeks of walking and exercise - delivered through videos…
- Trial name
- NCT06886607
- Testing
- the Mindfulness and Web-Based Physical Activity Program
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Selcuk University
Schizophrenia
A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of the drug SM-13496 compared to a placebo and to haloperidol in patients with schizophrenia.
- Trial name
- NCT00044044
- Testing
- Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg
- Where
- 34 sites in United States
- Volunteers
- 356 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
Repetitive Transcranial Magnetic Stimulation and Intermittent Theta Burst (iTBS) in Schizophrenia
The pilot studies have showed that theta burst stimulation (TBS) can have the more rapid and durable effects to the apply traditional rTMS protocols.
- Trial name
- NCT01315587
- Testing
- repetitive Transcranial Magnetic Stimulation (Magstim rapid2 ), repetitive Transcranial Magnetic Stimulation (Magstim rapid2), repetitive Transcranial Magnetic Stimulation(Magstim rapid2)
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- University of Tehran
Sleep Initiation and Maintenance Disorders
A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia
This study is to investigate the efficacy and safety of FK199B (Zolpidem MR Tablet) by polysomnography in patients with insomnia, excluding patients with schizophrenia or manic-depressive psychosis.
- Trial name
- NCT00999219
- Testing
- FK199B, Zolpidem
- Where
- 7 sites in Japan
- Volunteers
- 55 people
- Sponsor
- Astellas Pharma Inc
Schizophrenia
Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia
This will be a phase IV 20 -32 day prospective, double blind, double-dummy, randomised crossover study that will evaluate the effect of quetiapine XR and quetiapine IR on cognitive performance in patients with schizophrenia…
- Trial name
- eXtRa (NCT01213836)
- Testing
- Seroquel XR- quetiapine fumarate extended release, Seroquel IR - quetiapine fumarate
- Where
- 20 sites in Austria, Denmark and 3 more
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Women With Recent Diagnosis of Schizophrenia, Men With Recent Diagnosis of Schizophrenia
Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects
Individuals with schizophrenia have important and persistent deficits in multiple neurocognitive domains as well as in the Social Cognition (SC).
- Conditions
- Women With Recent Diagnosis of Schizophrenia, Men With Recent Diagnosis of Schizophrenia, Healthy Women, Healthy Men
- Trial name
- NCT02575209
- Testing
- GENDER
- Where
- Spain
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Corporacion Parc Tauli
Schizophrenia, Schizoaffective Disorder
Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia
In this trial, researchers aim to investigate if prolonged-release melatonin can facilitate the withdrawal of chronic benzodiazepine administration in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Affective Disorder
- Trial name
- SMART (NCT01431092)
- Testing
- Melatonin
- Where
- Denmark
- Volunteers
- 86 people
- Sponsor
- Lone Baandrup
First-episode Psychosis
Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode
Psychosis is a severe, common, and disabling psychological disorder. An epidemiological study conducted in England reported an incidence of 34 new cases per 100,000 person-years, with a peak between 16 and 19 years of age.
- Trial name
- PEPAMARKER (NCT05384392)
- Testing
- Recorded interview, Clinical scales, Blood sample
- Where
- 5 sites in France
- Volunteers
- 217 people
- Sponsor
- University Hospital, Brest
Schizophrenia, Psychosis
To Rescue Cognition With Valaciclovir
This is a one-week, randomized, double blind add-on study of valaciclovir versus placebo in 24 clinical patients with Schizophrenia according to DSM IV, currently experiencing psychosis as is defined by the positive items of the…
- Trial name
- NCT01364792
- Testing
- Valaciclovir
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- University Medical Center Groningen
Schizophrenia
Brief Group Psychoeducation for Schizophrenia
This study evaluates the addition of psychoeducation to treatment as usual in the treatment of adults with schizophrenia for relapse prevention.
- Trial name
- NCT02911519
- Testing
- Brief Group Psychoeducation, Treatment as Usual
- Volunteers
- 176 people
- Sponsor
- Salud Mental Integral S.A.S.
Schizophrenia, Animal-assisted Therapy
Animal-Assisted Therapy in Patients With Schizophrenia
Animal-assisted therapy (AAT) can be helpful to improve the psychiatric, emotional, physical,and social status in patients with physical and mental illness and the elderly.
- Trial name
- NCT04476836
- Testing
- Animal-Assisted Therapy
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Schizophrenia, Schizoaffective Disorder
PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders
The purpose of this study is to evaluate epidemiological characteristics of patients that experience relapse and need an admission in psychiatric acute units across Spain.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00399334
- Testing
- antipsychotic medications
- Volunteers
- 1,607 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia
A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia
To evaluate the safety of SEP-363856 (75 mg/day or 100 mg/day) administered for 52 weeks in adult participants with schizophrenia
- Trial name
- NCT07225712
- Testing
- SEP-363856
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia, Psychotic Disorders
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
The purpose of the study is to show that risperidone (an antipsychotic medication) combined with lorazepam (an anti-anxiety medication) is more effective than conventional therapy administered by intramuscular injection for…
- Conditions
- Schizophrenia, Psychotic Disorders, Emergency Treatment
- Trial name
- NCT00249171
- Testing
- risperidone
- Volunteers
- 226 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia
The purpose of this study is to compare the effect of oral paliperidone extended-release and oral risperidone immediate-release on cognitive function, especially the category fluency of Cognitive Abilities Screening Instrument…
- Trial name
- NCT01670071
- Testing
- Paliperidone extended-release, Risperidone immediate-release
- Where
- 3 sites in Taiwan
- Volunteers
- 17 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Paranoid Schizophrenia, Schizophrenia
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)
The purpose of this study is to determine the safety and effectiveness of an investigational drug for the treatment of cognitive impairment in patients with schizophrenia.
- Trial name
- NCT00482430
- Testing
- MK0557
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC